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REVIEW
Abstract: Immunotherapy results in a small overall survival advantage in metastatic renal
cell carcinoma (RCC), but there is a need to develop more effective systemic therapies.
Angiogenesis has an important role in the pathophysiology of RCC and vascular endothelial
growth factor (VEGF) is a key mediator of this process. Sorafenib (BAY 43-9006) is a new
agent belonging to a class of drugs called kinase inhibitors and inhibits the VEGF, platelet-
derived growth factor (PDGF), and c-KIT receptor tyrosine kinases, amongst others. Sorafenib
has shown significant activity with manageable toxicity in metastatic RCC in phase 2 studies
in patients pretreated with immunotherapy, whilst prolonged progression-free survival in
comparison with placebo in a phase 3 study has been reported. Further phase 3 trials in advanced
disease are ongoing and a trial of adjuvant sorafenib therapy in RCC is planned.
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Introduction
Epidemiology and pathology of renal cell carcinoma
Carcinoma of the kidney accounts for 2%–3% of cancers (Landis et al 1999; Parkin
et al 1999) and increased in incidence in the UK between 1991 and 2000 by almost
20% (Toms 2004). The reason for this increase in incidence is unknown.
Approximately 70% of patients with renal cell carcinoma (RCC) present with localized
disease that is potentially curable with nephrectomy.
Renal cell carcinomas have been classified histologically as clear cell (~60%–
80%), papillary (~10%–15%), chromophobe (~5%–10%), medullary and collecting
duct (< 1% each) (Cheville et al 2003; Beck et al 2004; Ficarra et al 2005). Clear cell
histology is associated with a poorer outcome than either chromophobe or papillary
histology (Cheville et al 2003; Beck et al 2004) for resectable disease although the
reverse is true for metastatic disease (Motzer et al 2002).
Von Hippel-Lindau (VHL) disease is inherited in an autosomal dominant manner
(Latif et al 1993) and is characterized by an increased incidence of hemangioblastomas
of the retina and central nervous system (CNS) and clear cell carcinoma of the kidney
(Kim and Kaelin 2004). Individuals with this disease are born with a mutated version
of the VHL gene; tumor development is associated with subsequent somatic mutation
of the remaining allele. Von Hippel-Lindau disease is the commonest basis for
inherited RCC and is directly relevant to sporadic clear cell renal carcinoma as
inactivation of both VHL genes occurs via mutation in approximately 40%–50% of
cases (Brauch et al 2000; Kondo et al 2002; Yao et al 2002) and via promoter
hypermethylation in 5%–20% of cases (Herman et al 1994; Clifford et al 1998; Brauch
et al 2000; Kondo et al 2002; Yao et al 2002; Dulaimi et al 2004).
The VHL protein is involved in the cellular response to hypoxia (Figure 1). Under
normoxic conditions, the VHL protein is bound to hypoxia inducible factor-1α
(HIF-1α) and HIF-2α, which as a result become ubiquitinated and tagged for
degradation in the proteasome (Ohh et al 2000). In hypoxic conditions or in the
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absence of VHL, HIF-1a accumulates, stimulating the
production of growth factors such as vascular endothelial
growth factor (VEGF), transforming growth factor a
(TGFα) and platelet-derived growth factor (PDGF), which
in turn stimulate cellular proliferation and angiogenesis.
Treatment of metastatic RCC
The management of metastatic RCC is an important problem
given that approximately 30% of patients initially present
with disseminated disease. Furthermore, approximately 30%
of patients treated with curative intent for localized disease
subsequently relapse. Metastatic RCC is incurable and
treatment intent is palliative. The prognosis for metastatic
RCC is poor: median survival is 10–12 months (Selli et al
1983; MRC 1999; Motzer et al 2004a, 2004b).
Response rates to hormonal agents (Harris 1983) and to
combination chemotherapy (Yagoda and Bander 1989) in
metastatic RCC are 5%–10%, which may reflect the natural
history of the disease rather than the effect of treatment
(Oliver et al 1989; Gleave et al 1998). Subcutaneous
interferon (IFN) therapy produces response rates of 10%–
20% with median response durations of 3 to 16 months
(Horoszewicz and Murphy 1989). Randomized controlled
trials have reported a survival advantage with IFN therapy
compared with non-immunotherapy (MRC 1999; Pyrhonen
et al 1999) and a Cochrane review and meta-analysis has
confirmed the value of IFN-α in metastatic RCC (Coppin
et al 2005). In nonrandomized trials in metastatic RCC,
approximately 10% of patients have a complete response to
treatment with high dose intravenous interleukin-2 (HDIV
IL-2) and in 70%–80% of these patients, disease control is
prolonged (Rosenberg et al 1998) but this therapy causes
substantial toxicity.
Surgery to remove the primary lesion in metastatic RCC
results in a survival benefit when immunotherapy is given
post-operatively. This has been reported in two randomized
trials, Southwest Oncology Group (SWOG) 8949 (Flanigan
et al 2001) and European Organization Research and
Treatment of Cancer (EORTC) 30947 (Mickisch et al 2001;
Flanigan et al 2004). Both trials randomized patients with
good performance status to nephrectomy followed by
treatment with IFN-α versus treatment with IFN-α alone.
Median survival increased from 8 to 11 months and from 7
to 17 months respectively in the nephrectomy groups.
Figure 1 Under normoxic conditions the VHL protein binds to HIF-α which is ubiquitinated and tagged for degradation in the proteasome. In hypoxic conditions or
in the absence of VHL, HIF-α accumulates, and stimulates the production of growth factors such as VEGF, TGFα, and PDGF. These factors act on receptor TKs,
stimulating cell proliferation and angiogenesis.
Abbreviations: HIF-α, hypoxia inducible factor-α; PDGF, platelet-derived growth factor; TGFα, transforming growth factor α; TK, tyrosine kinase; VEGF, vascular
endothelial growth factor; VHL, Von Hippel-Lindau.Therapeutics and Clinical Risk Management 2006:2(1) 89
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In summary, immunotherapy for metastatic RCC has
significant toxicity and modest efficacy, but offers the
possibility of prolonged disease control or cure. Careful
patient selection for such therapy is vital: recent data suggest
that high tumor carbonic anhydrase IX (Atkins et al 2005)
expression is predictive of prolonged median survival after
IL-2-based therapy; this antigen therefore may be a useful
marker in selecting patients for therapy, but there is a clear
need for effective treatment options in the majority of
patients who do not benefit from immunotherapy.
Kinase inhibitors
Introduction
Sorafenib (Nexavar, BAY 43-9006) is a small molecule drug
that, among other targets, inhibits tyrosine kinases (TKs),
enzymes that catalyze the transfer of γ-phosphate groups
from adenosine triphosphate (ATP) to the hydroxyl groups
of tyrosine residues on target polypeptides or proteins. The
phosphorylation of proteins such as signaling molecules is
often an activating event that in tumors can cause increased
cellular proliferation and promote angiogenesis and
metastasis.
Tyrosine kinases can be categorized as receptor- and non-
receptor kinases. Receptor TKs, eg, the epidermal growth
factor receptor (EGFR/ERBB1), span the cell membrane
and transduce extracellular signals to the cell interior.
Ligand-binding induces autophosphorylation of the
cytoplasmic domain, conformational changes, and increased
TK activity. Multiple downstream intracellular signaling
pathways (Schlessinger 2000) such as phosphoinositol
3´-kinase, Ras/Raf/mitogen-activated protein kinase
kinase(MEK)/extracellular signal-regulated kinase (ERK)
and protein kinase C may as a result be activated. Non-
receptor TKs, eg, c-ABL(Abelson), relay intracellular
signals and can be activated in various ways such as by
phosphorylation by other kinases.
Tyrosine kinases may be dysregulated in cancer cells in
a number of ways. An example is B cell receptor (BCR)–
ABL in chronic myelogenous leukemia (CML) which results
from the balanced (9;22) chromosomal translocation. This
causes the production of the nonreceptor TK BCR–ABL
fusion protein. A domain in BCR overcomes the auto-
inhibition of ABL, resulting in constitutive TK activation.
A second mechanism of TK dysfunction in malignant cells
is via the overexpression of a TK or its ligand; eg, the
overexpression of VEGFR, PDGFR, or EGFR or their
ligands in RCC (Gomella et al 1989; Mydlo et al 1989; Atlas
et al 1992; Uhlman et al 1995; Iliopoulos et al 1996; Ramp
et al 2000; Gunningham et al 2001; Na et al 2003;
Sulzbacher et al 2003, Yildiz et al 2004; Minardi et al 2005;
Xu et al 2005). A third mechanism is via increased sensitivity
of a receptor to its ligand, eg, mutations in EGFR in some
non-small cell lung cancers (NSCLCs) resulting in altered
receptor signaling (Pao et al 2004; Sordella et al 2004). It is
unknown whether or not RCC is dependent on, or driven
by, changes in receptor sensitivity to ligands.
Drugs that disrupt TK signaling are used increasingly
in the treatment of cancer. There are 2 classes of such drugs:
monoclonal antibodies, eg, trastuzumab, cetuximab, and
bevacizumab and small molecules (‘kinase inhibitors’), eg,
imatinib, erlotinib, gefitinib, sorafenib, (BAY 43-9006) and
sunitinib (SU011248).
Kinase inhibition by monoclonal
antibodies
Monoclonal antibodies directed against receptor TKs or their
ligands preventing ligand binding and receptor internaliza-
tion. For example, cetuximab and trastuzumab bind to the
EGFR and HER-2/neu receptor TKs respectively; these
molecules are often overexpressed in colorectal (EGFR) and
breast (HER-2/neu) cancers and the efficacy of cetuximab
in the treatment of metastatic colorectal cancer (Cunningham
et al 2004) and trastuzumab in the treatment of breast cancer
(Slamon et al 2001; Piccart-Gebhart et al 2005; Romond et
al 2005) has been demonstrated clearly. Bevacizumab is
directed against VEGF, a key regulator of angiogenesis
(Ferrara et al 2003, 2004), a process vital for tumor growth
(Folkman 1972). In metastatic RCC, when bevacizumab is
used as monotherapy, an increase in time to disease
progression has been reported (Yang et al 2003).
Kinase inhibition by small molecules
Small molecule drugs disrupt TK signaling by preventing
the binding of either protein substrates or ATP. For example,
imatinib is a 2-phenylaminopyrimidine that inhibits the
BCR-ABL fusion protein in CML (Druker et al 2001) and
c-KIT (CD 117) in gastrointestinal stromal tumors (GISTs)
(van Oosterom et al 2001) and has made a dramatic impact
on the management of these diseases. The impact of small
molecule kinase inhibitors has however been more modest
in other settings. For example, neither gefitinib nor erlotinib,
when used in combination with standard chemotherapy in
the first-line treatment of NSCLC, show a benefit over
chemotherapy alone (Giaccone et al 2004; Herbst et al
2004). Interestingly, both drugs have shown limited efficacy
as single agents in NSCLC (Kris et al 2003; Shepherd et alTherapeutics and Clinical Risk Management 2006:2(1) 90
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2005), but the clinical benefit is mainly in specific subgroups
of patients (Lynch et al 2004; Paez et al 2004; Pao et al
2004) such as female nonsmokers with adenocarcinomas.
These findings highlight the potential need for careful patient
selection for kinase inhibitor treatment.
This review will focus on the small molecule kinase
inhibitor sorafenib in the treatment of RCC.
Sorafenib (Nexavar, BAY 43-9006)
in RCC
Introduction
Sorafenib is an orally administered bi-aryl urea that was
designed originally as an inhibitor of BRAF and CRAF,
non-receptor serine threonine kinases. These kinases are
members of the Raf/MEK/ERK intracellular signaling
cascade, a downstream effector of Ras, which in turn can
be activated by upstream receptor TK stimulation (Figure 2).
Activation of the Raf/MEK/ERK cascade leads to changes
in metabolism, transcription, and intracellular cytoskeletal
arrangements (Marais et al 1997). This pathway is known
to be involved in tumor cell survival and proliferation and
is a therapeutic target in cancer (Sridhar et al 2005). It is
unclear, however, whether dysfunction of this signaling
cascade is important in RCC, although some data suggest
that it may be relevant (Fujita et al 1988; Oka et al 1995). In
addition to inhibition of Raf family non-receptor kinases,
sorafenib also inhibits a number of receptor TKs in cell-free
assays known to be involved in angiogenesis and
tumorigenesis such as VEGFR2, VEGFR3, fetal liver tyrosine
kinase 3 (Flt-3), c-KIT, and PDGFR. Sorafenib is also known
to inhibit the BRAF mutant V600E which is present in over
half of malignant melanomas (Davies et al 2002). This
mutation is not reported in RCCs (Nagy et al 2003).
Preclinical data
In cell-free biochemical assays, varying concentrations of
sorafenib were assayed for their capacity to inhibit
phosphorylation of the non-receptor TK mitogen-activated
protein kinase kinase (MEK) by the catalytic domains of
Figure 2 Ligand binding to a receptor TK induces oligomerization and autophosphorylation of the cytoplasmic domain and contingent increased TK activity. Multiple
downstream intracellular signaling pathways such as Ras/Raf/MEK/ERK may as a result be activated, resulting in proliferation, angiogenesis and metastasis. Sorafenib is
a dual action kinase inhibitor, targeting receptor TKs and BRAF.
Abbreviations: ERK, extracellular signal-mediated kinase; MEK, mitogen-activated protein kinase kinase; TK, tyrosine kinase.Therapeutics and Clinical Risk Management 2006:2(1) 91
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BRAF and V600E BRAF (Wilhelm et al 2004). Potent
inhibition of both BRAF and V600E BRAF was noted with
IC50 values between 20–40 nmol/L. The related CRAF
(Raf-1) kinase was inhibited with an IC50 of less than
10 nmol/L (Table 1). The IC50 values for MEK and ERK
were greater than 10 000 nmol/L. The receptor TKs c-KIT,
murine PDGFR-β, and Flt-3 were inhibited with IC50 values
in the range 40–80 nmol/L whilst VEGFR2 was inhibited
with an IC50 of approximately 90 nmol/L. The IC50 values
for the receptor TKs EGFR and HER-2 were greater than
10 000 nmol/L. Sorafenib has been co-crystallized in
complex with BRAF and V600E BRAF (Wan et al 2004).
The distal pyridyl ring of sorafenib was shown to interact
with 3 amino acids in the ATP adenine-binding pocket and
in addition, the urea moiety formed hydrogen bonds within
the enzyme. As a result, sorafenib is thought to promote the
formation of the inactive form of BRAF.
Sorafenib inhibited activation of the Raf/MEK/ERK
pathway in a number of cell lines in Western blot assays
and pERK immunoassays (Wilhelm et al 2004). In MDA-
MB-231 breast cancer cell lines, sorafenib completely
blocked activation of the Raf/MEK/ERK pathway. Dose-
dependent inhibition of both MEK and ERK basal
phosphorylation was noted (IC50 40 nmol/L and 100 nmol/L,
respectively). Inhibition of ERK phosphorylation by
sorafenib was also observed in the pancreatic tumor cell
line Mia PaCa 2 and the colon tumor cell lines HCT116 and
HT-29 by Western blot analysis. Similar results were
reported in the LOX melanoma and pancreatic BxPC-3 cell
lines using the Bio-Plex pERK immunoassay, but no
inhibition of ERK phosphorylation was noted in the non-
small cell lung cancer cell lines A549 and NCI-H460 at
sorafenib concentrations up to 10 000 nmol/L.
Inhibition of VEGFR2 autophosphorylation by sorafenib
has been investigated in the HUVEC (human umbilical vein
endothelial cell) and NIH 3T3 VEGFR2 (murine embryonic
fibroblast) cell lines. At a sorafenib concentration of
100 nmol/L, over 50% inhibition of VEGFR2 phosphor-
ylation was noted in HUVEC cell lysates. Sorafenib also
inhibited PDGFR autophosphorylation in primary human
aortic smooth muscle cells (HAoSMCs); Flt-3 was also
sensitive to inhibition of receptor phosphorylation by
sorafenib in cell-based assays.
Sorafenib has also demonstrated activity in xenograft
mouse models of human colon, lung, breast, pancreatic, and
melanoma neoplasms (Wilhelm et al 2004). Mice were
treated with sorafenib at doses from 7.5 mg/kg to 60 mg/kg
orally for 9 days. Tumor growth inhibition was dose-
dependent and mice treated with sorafenib maintained body
mass in comparison with untreated controls, ie, drug toxicity
was not excessive. Complete inhibition of tumor growth was
noted during sorafenib administration at 30 mg/kg to
60 mg/kg in the HT-29, Colo-205, and DLD-1 colorectal
models, the MDA-MB-231 breast model, and in the A549
NSCLC model. All these cell lines express a kRas and/or a
BRAF mutation that constitutively activates signaling
through the Raf/MEK/ERK pathway. Interestingly, complete
inhibition of tumor growth was not seen in the NCI-H460
NSCLC model at a dose of 60 mg/kg despite the presence
of a kRas mutation, suggesting that a mutation in the Raf/
MEK/ERK pathway is not in itself predictive of sorafenib
sensitivity. The fact that A549 and NCI-H460 growth was
inhibited in vivo is of interest given that sorafenib did not
reduce ERK phosphorylation in these cell lines in vitro (see
above) and suggests that another mechanism, eg, inhibition
of other TKs such as c-KIT, Flt-3, and VEGFR2 may be
responsible. In parallel experiments, mice similarly treated
with sorafenib were culled and Western blotting to
investigate MEK and ERK activation was performed. In the
HT-29 and MDA-MB-231 models, levels of phosphorylated
MEK and ERK were reduced in treated animals in
comparison with untreated controls, thus tumor growth
retardation was correlated with inactivation of the Ras/Raf/
MEK/ERK pathway. In Colo-205 xenografted tumors, ERK
phosphorylation was not inhibited by sorafenib as assayed
by Western blotting and immunohistochemistry, although
it was blocked in cell culture, suggesting that ERK may be
activated by a mechanism independent from the Ras/Raf/
MEK pathway in these tumors. Given that sorafenib inhibits
receptor TKs known to be involved in angiogenesis,
microvessel area (MVA) and density (MVD) were assessed
in the xenograft tumor models. Sorafenib treatment resulted
in a reduction in both parameters in HT-29, Colo-205, and
MDA-MB-231 tumors.
Table 1 Targets of sorafenib in cell-free assays
Kinase IC50
CRAF < 10nM
mVEGFR3 10–20 nM
mPDGFR, BRAF, BRAF V600E 20–40 nM
Flt-3, c-KIT 40–80 nM
VEGFR2 80–160 nM
MEK, ERK, EGFR, HER-2 Inactive at 10 000 nM
Abbreviations: EGFR, epidermal growth factor receptor; ERK, extracellular
signal-mediated kinase; Flt-3, fetal liver tyrosine kinase 3; HER-2, human
epidermal growth factor receptor 2; IC50, concentration of drug required to
cause 50% inhibition of an enzyme; m, murine; MEK, mitogen-activated protein
kinase kinase; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular
endothelial growth factor receptor.Therapeutics and Clinical Risk Management 2006:2(1) 92
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In summary, the preclinical data demonstrate that
sorafenib inhibits multiple receptor TKs involved with tumor
angiogenesis and non-receptor TKs of the Raf family
involved with tumor cell proliferation, and that both
mechanisms may account in part for the activity of the drug.
Phase 1 data
Four phase 1 studies in 163 patients identified 400 mg twice
daily continuous dosing as the recommended phase 2 dose
of sorafenib (Strumberg et al 2002, 2005; Awada et al 2005;
Clark et al 2005; Moore et al 2005). Drug-related toxicities
were reported in approximately three quarters of subjects
and were generally mild to moderate. The most frequent
toxicities were diarrhea (~50% of patients), skin toxicity
(~50%), fatigue (~40%), anorexia (~40%), alopecia (~25%),
and nausea (~20%). Stomatitis, pancreatitis, and elevation
of serum bilirubin were reported in less than 5% of patients.
The commonest dose-limiting toxicities were grade 3
diarrhea, fatigue, and skin toxicity whilst grade 3
pancreatitis, anorexia, nausea, stomatitis, alopecia, and
elevation of bilirubin were rarely reported. All toxicities were
reversible on cessation of sorafenib.
Sorafenib was absorbed at a moderate rate after the first
dose and Cmax occurred between 2.5 and 12.5 hours after
administration. Plasma concentrations of sorafenib
subsequently decreased slowly and there was no dose-
dependency in plasma concentration-time profiles after the
first dose of 100 mg to 800 mg twice daily. Significant
accumulation in plasma was noted after multiple twice daily
administration of sorafenib. Food intake prior to dosing had
no relevant impact on sorafenib pharmacokinetics apart from
a mild prolongation of tmax. Area under the curve (AUC)
and Cmax values were variable following multiple twice daily
doses of sorafenib and maximum mean AUC0-12 values were
noted at 600 mg twice daily although there was little
difference between 400 mg and 600 mg twice daily.
The effect of sorafenib on phorbol myristate acetate
(PMA)-stimulated ERK phosphorylation in peripheral blood
lymphocytes (PBLs) was studied using flow cytometry
(Strumberg et al 2005). Almost complete inhibition of PMA-
stimulated ERK phosphorylation was reported at doses of
400 mg twice daily continuous dosing and above on day
21, confirming biological activity at these doses.
Seven patients with RCC were treated in the phase 1
studies; there was 1 partial response of 104 days duration
(Awada et al 2005) and 5 patients had stable disease: 1 of
the 5 patients, who had previously received 3 prior lines of
treatment, experienced disease stabilisation for almost 2
years (Strumberg et al 2005). These findings provided the
basis for phase 2 studies of sorafenib in RCC.
Phase 2 data
The results of a phase 2 multicenter randomized dis-
continuation trial (RDT) of sorafenib in RCC were updated
recently in abstract form (Ratain et al 2005). The RDT design
allows the disease stabilizing effect of a study agent to be
distinguished from slowly-growing disease (Rosner et al
2002; Stadler et al 2005). All patients are treated initially
with the study agent (stage 1) and those with stable disease
undergo double-blinded randomization between continued
therapy and placebo (stage 2). Patients with responses at
the end of stage 1 continue the study agent until disease
progression whilst therapy is stopped in patients with
progressive disease at the end of stage 1.
The phase 2 RDT of sorafenib in metastatic RCC
investigated the effect of the drug on tumor growth in
patients with stable disease after 12 weeks of treatment in
stage 1. Two hundred and two patients with advanced RCC
were treated at a dose of 400 mg orally twice daily in stage 1.
All histological subtypes were eligible and the study
population was heterogeneous with regard to prior therapy;
most patients received sorafenib as second-line (56%) or
third-line (34%) therapy. All patients were of PS < 1 and
56% had undergone nephrectomy. Sixty five patients with
stable disease (response between 25% tumor reduction and
25% tumor growth) at 12 weeks were randomized to
sorafenib (n = 32) or placebo (n = 33); patient characteristics
were matched between the groups. After 24 weeks, 6 patients
(18%) on placebo were progression-free compared with 16
patients (50%) on sorafenib (p = 0.0077). Median pro-
gression-free survival (PFS) after randomization was greater
with sorafenib than placebo (23 versus 6 weeks, p = 0.0001,
hazard ratio [HR] 0.29). Sorafenib was restarted in the 25
patients who progressed on placebo after a median time from
randomization of 7 weeks. Median PFS after restarting
sorafenib in these patients was 24 weeks and 13 patients
remained on therapy at the time of reporting. The most
common drug-related toxicities were rash (62%), hand-foot
skin reaction (61%) and fatigue (56%). The authors conclude
that sorafenib has a marked effect on PFS in metastatic RCC
and an acceptable toxicity profile and that the trial
demonstrates the utility of the RDT design. A randomized
phase 2 trial comparing sorafenib with IFN as first-line
therapy for metastatic RCC recently completed accrual.Therapeutics and Clinical Risk Management 2006:2(1) 93
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Phase 3 data
The results of a phase 3 multicentre randomized placebo-
controlled double-blind trial of sorafenib in advanced RCC
in patients who had progressed after 1 prior systemic therapy
have also been updated in abstract form (Escudier et al
2005a). The primary endpoint of the trial was overall survival
(OS) in patients with advanced clear cell renal carcinoma
randomized to sorafenib versus placebo and best supportive
care. The results of a planned analysis on the secondary
endpoint, progression-free survival (PFS) were reported.
Subjects had PS 0 or 1, had received one prior systemic
therapy for advanced RCC and were randomized to receive
continuous oral sorafenib 400 mg twice daily or placebo
and best supportive care. At the time of the PFS analysis,
769 of the planned 884 patients had been randomized and
342 PFS events had been reported. Baseline prognostic
characteristics were similar between both groups; 93% had
undergone nephrectomy and 82% of patients had received
prior cytokine therapy.
Median PFS was 24 weeks for sorafenib versus 12 weeks
for placebo (HR 0.44; p < 0.00001) and the 12 week
progression-free rate was 79% for sorafenib versus 50%
for placebo (Figure 3). Reported toxicities for sorafenib
versus placebo were diarrhea (33% versus 10%), hand-foot
skin reaction (27% versus 5%), rash (34% versus 13%),
fatigue (26% versus 23%) and hypertension (11% versus
1%). Grade 3 or 4 adverse events were reported in 30% of
patients on sorafenib versus 22% of patients on placebo.
Response data were updated recently in an oral
presentation (Escudier et al 2005b). 903 patients had been
enrolled by the data cut off on May 31st 2005. At this time,
there had been 1 complete response to treatment (in the
sorafenib arm) and 51 partial responses (43 in the sorafenib
arm versus 8 in the placebo arm, 10% versus 2%). Stable
disease was reported in 333 patients in the sorafenib arm
versus 239 patients in the placebo arm (74% versus 53%)
and progressive disease in 56 patients in the sorafenib versus
167 in the placebo group (12% versus 37%). Many of the
patients with stable disease in the sorafenib group had tumor
regression insufficient to meet the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria for a partial
response; further follow-up is needed to ascertain the clinical
significance of this observation. Preliminary overall survival
data from a planned interim analysis after 220 events were
also presented. Median overall survival in the placebo group
was 14.7 months and had not been reached in the sorafenib
group (HR 0.72; p = 0.018). The threshold for statistical
significance for this interim analysis was p < 0.0005 and so
the results, whilst encouraging, should be interpreted with
caution.
Key outstanding issues
Several questions concerning the use of sorafenib in RCC
are unresolved.
First, the mechanism of action of sorafenib in vivo has
not been established. The administration of neoadjuvant
sorafenib with biopsies both before and on treatment may
allow this issue to be addressed (Potti and George 2004).
Neoadjuvant therapy may also allow the identification of
biomarkers of response prediction and radiological changes
can be correlated with pathological and molecular changes
as a result of therapy (Chang et al 1999).
Second, there are no data on the treatment of non-clear
cell renal carcinoma with sorafenib; VHL dysfunction is
Figure 3 Tumor shrinkage after 6 weeks of therapy with sorafenib (reproduced
with permission from Bernard Escudier).Therapeutics and Clinical Risk Management 2006:2(1) 94
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less common in non-clear cell than clear cell carcinoma and
it may that antiangiogenic therapies have less efficacy in
this setting but this premise has not been tested
experimentally.
Third, there are few data on the efficacy of sorafenib by
site of metastatic disease. Data from the phase 3 trial of
sorafenib versus placebo (Escudier et al 2005c) indicate that
PFS is superior in the sorafenib group irrespective of the
presence or absence of lung or liver metastases. It is unclear
whether or not sorafenib or any small molecule kinase
inhibitor crosses the blood brain barrier and would therefore
be active in the setting of brain metastases. Conflicting data
have been reported from the treatment of NSCLC with the
EGFR inhibitors gefitinib and erlotinib. The CNS was the
first site of relapse in 7/21 patients with adenocarcinoma of
the lung relapsing after responding to erlotinib therapy in a
recent case series. Four of the patients with disease
recurrence in the CNS had stable disease in the lung (Omuro
et al 2005), suggesting that erlotinib may not penetrate the
blood brain barrier. In contrast, in a further case series
(Namba et al 2004), 15 patients with recurrent NSCLC with
brain metastases were treated with gefitinib and a response
rate of 60% was reported for both brain metastases and
primary lesions.
Fourth, an intriguing aspect of the use of kinase inhibitors
for the treatment of cancer has been reported in the treatment
of gastrointestinal stromal tumors (GISTs) with imatinib.
In this disease, imatinib dose can be increased safely on
disease progression and approximately a quarter of patients
will experience renewed disease stabilisation as a result
(Zalcberg et al 2005). This begs the question as to whether
this observation is specific to either kinase inhibitors or to
GISTs. Although no trial data have been reported,
anecdotally, sorafenib toxicity often attenuates with
prolonged therapy, which allows dose escalation. The reason
for this reduction in toxicity over time is unknown.
Fifth, there are interesting comparisons between
sorafenib and other kinase inhibitors active in RCC such as
sunitinib (SU011248). Sunitinib and sorafenib inhibit a
similar spectrum of TKs (with the exception that Raf kinases
are not inhibited by sunitinib), but it is clear that the toxicity
profile differs between the drugs: skin toxicity is probably
the most problematic side effect of sorafenib (Robert et al
2005), whilst sunitinib can cause significant myelo-
suppression (Faivre et al 2006; Motzer et al 2006). Given
that kinase inhibitors are often cytostatic, long term therapy
is likely in many cases and toxicity is likely to be a key
issue in selection of therapy. The efficacy of sorafenib and
sunitinib may also differ. Partial or complete responses to
treatment are relatively rare with sorafenib, but disease
stabilization is often seen. In contrast, responses to treatment
appear more common with sunitinib in advanced RCC
(Motzer et al 2006). It is tempting to speculate that the
toxicity and efficacy profiles of sunitinib and sorafenib in
advanced RCC reflect differences in the spectrum of kinases
inhibited, but there are no data to support such a contention.
Sixth, data on the combination of sorafenib with other
other active therapies in the treatment of RCC are limited.
However, in an interim analysis of a phase II trial, sorafenib
(400 mg twice daily) in combination with IFN-α 2b (10 MIU
three times weekly) showed 5% had a RECIST-defined
complete response and 32% had a partial response, which
generally occurred within the first 2 cycles. A further 47%
of patients had stable disease, including two patients (11%)
who experienced 20% tumor regression. This combination
was well tolerated with a two week treatment break between
every 8-week cycle. Clearly these are early results but must
at least be considered promising. Semaxinib (SU5416), an
inhibitor of the VEGFR1 and VEGFR2 TKs, has also been
studied in combination with INF-α therapy in a phase 2
trial (Lara et al 2003). However, in this study there were no
responses to therapy in 23 patients and significant toxicity
was reported including 3 on-study deaths. Semaxinib was
given intravenously twice weekly with pulsed steroids, the
latter to prevent allergic reactions as it is soluble only in
Cremophor. The authors of the study speculate that pulsed
steroids may have contributed to the regimen’s toxicity and
could have attenuated the antiangiogenic
 and immuno-
modulatory effects of IFN. The EGFR receptor TK inhibitor
erlotinib has been administered with bevacizumab in a phase
2 trial in metastatic RCC recently reported in abstract form
(Spigel et al 2005). Toxicity was generally manageable
although 1 episode of grade 4 toxicity was reported (a
gastrointestinal bleed). In summary, the safety of combining
a kinase inhibitor with a monoclonal antibody but not
with IFN has been established in small studies. Trials
investigating the combination of sorafenib with
bevacizumab, IFN, and erlotinib, are ongoing.
Seventh, the questions of how systemic treatment might
be sequenced and to what extent there is cross-resistance
between different kinase inhibitors and other systemic
therapies in RCC are important. Controversy still surrounds
the optimum immunotherapy of metastatic RCC (Larkin and
Gore 2005) and biomarkers are needed to select patients
for different therapies. For example, carbonic anhydrase IX
expression has been reported as a predictor of outcomeTherapeutics and Clinical Risk Management 2006:2(1) 95
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in patients with RCC receiving IL-2-based therapy (Atkins
et al 2005) and microarray technology has been used to
classify RCCs (Kosari et al 2005; Yang et al 2005). The use
of such techniques in other tumor types has generated
interest (Bhattacharjee et al 2001; Beer et al 2002; Pomeroy
et al 2002; Rosenwald et al 2002; van de Vijver et al
2002; Yeoh et al 2002; Iizuka et al 2003; Ramaswamy et al
2003), but presents considerable challenges (Michiels et al
2005).
Finally, a further area for the investigation of sorafenib
in RCC is as adjuvant therapy. Although immunotherapy
has proven efficacy in metastatic disease, no benefit has been
shown for adjuvant therapy (Pizzocaro et al 2001; Clark et
al 2003; Messing et al 2003) and in fact a reduction in overall
survival has been reported with immunotherapy in
comparison with placebo (Atzpodien et al 2005). Given the
activity of sorafenib and other kinase inhibitors in advanced
disease, there is a logical interest in evaluating these drugs
in early stage disease to minimize the likelihood of relapse
after surgery and toxicity is again important as cytostatic
adjuvant therapies may be administered for prolonged
periods.
Conclusions
Sorafenib inhibits multiple targets including the BRAF,
V600E BRAF, and CRAF non-receptor TKs and the VEGF,
PDGF, and c-KIT receptor TKs. It is orally administered
and has shown significant activity with manageable toxicity
in a phase 3 trial in metastatic RCC in immunotherapy-
refractory patients. Given the activity of sorafenib in
advanced RCC, investigation in the adjuvant setting to
attempt to minimize the risk of disease recurrence is planned.
There is also interest in the use of kinase inhibitors in the
neoadjuvant setting to investigate the mechanism of drug
action in vivo and to identify biomarkers of response to
therapy.
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